Compare AMCX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | BCYC |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.9M | 360.7M |
| IPO Year | 2011 | 2019 |
| Metric | AMCX | BCYC |
|---|---|---|
| Price | $7.92 | $5.12 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $7.00 | ★ $13.90 |
| AVG Volume (30 Days) | 331.2K | ★ 593.0K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,311,801,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.41 | $4.24 |
| 52 Week High | $10.28 | $9.55 |
| Indicator | AMCX | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 54.09 |
| Support Level | $7.77 | $5.03 |
| Resistance Level | $8.19 | $5.90 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 99.32 | 77.48 |
AMC Networks owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.